Vall d'Hebron Institute of Oncology (VHIO) at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Vall d'Hebron Institute of Oncology (VHIO) brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on CAR T cell therapy for solid tumours. One line builds CAR T cells that recognise only mutated FGFR2 in endometrial cancer, and another reports a first-in-human trial of a CAR aimed at a HER2 variant.

OrganizationESGCT 2026 Attendance
Poster
Wed Oct 28
1:30pm–3:30pm
Development of FGFR2 Mutation-Selective CAR T Cells for Endometrial Cancer
Immunotherapy and CAR T cells
Poster
Thu Oct 29
2:00pm–4:00pm
First clinical evaluation of p95HER2.CAR-TECH2Me in HER2-positive solid tumors: CATHERINE phase I trial
Immunotherapy and CAR T cells

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Vall d'Hebron Institute of Oncology (VHIO)

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction